Sign up to watch this video
Free access to all Sound Bites content
Dr. Ghaith Abu-Zeinah reviews the risks and threats in essential thrombocythemia (Video 2/3)
Published 1 week
Medical Professional
Risk and Threats in ET
Related Videos
Dr. Sandip Patel describes re-challenging with chemotherapy in patients who received 1L osimertinib + chemotherapy. (Video 3/3)
Sandip Patel, MD
Dr. Joshua Richter highlights the patient types that may benefit most from mezigdomide (Video 3/3)
Joshua Richter, MD
Dr. Joe Mendez reviews the watch and wait vorasidenib patient profile in low-grade gliomas (Video 3/3)
Joe Mendez, MD
Dr. Ghaith Abu-Zeinah reviews the risks and threats in essential thrombocythemia (Video 2/3)
Ghaith Abu-Zeinah, MD
Dr. Laura van ‘t Veer describes the residual cancer burden with ctDNA in breast cancer (Video 3/3)
Laura van 't Veer, PhD
Dr. Sandip Patel reviews the benefit of adding local consolidative treatment to 1L osimertinib in EGFRm mNSCLC. (Video 2/3)
Sandip Patel, MD
IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America
© 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.